StockMacro
Menu

Kestra Medical Technologies

$25.10 +15% in 6 monthsMarket cap $1.5B

KMTS on XNAS, Health Care, Kestra Medical Technologies, Ltd., job postings

Measures activity, not value. Not investment advice.

Revenue jumped 60% to $31M in the quarter but losses reached $149.9M over 12 months.

  • BadShort interest up 20% from the report two weeks earlier, now 6.9%
  • BadFree cash flow was negative $122.8M over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 31 Jul 2026

Kestra Medical Technologies Ltd is a commercial-stage wearable medical device and digital healthcare company focused on connected monitoring, therapeutic intervention, and data-driven clinical insights for cardiovascular disease. It has developed and is commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. The platform is anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. The platform also includes digital patient engagement and clinical workflow solutions.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
443
Website
kestramedical.com
Listed
Nasdaq, US
Last results
14 Sep 2026
Next results
expected around 30 Nov 2026 (an estimate: a year ago it reported on 1 Dec 2025)
Revenue and net income per quarter. Quarter to 31 Jul 2026: revenue $31.0M, net loss $44.1M.
Quarter to 31 Jul 2024: revenue $12.8M, net income -$19.9MQuarter to 31 Jul 2024: revenue $12.8M, net income -$19.9MQuarter to 31 Oct 2024: revenue $14.7M, net income -$20.4MQuarter to 31 Oct 2024: revenue $14.7M, net income -$20.4MQuarter to 31 Jan 2025: revenue $15.1M, net income -$21.5MQuarter to 31 Jan 2025: revenue $15.1M, net income -$21.5MQuarter to 30 Apr 2025: revenue $17.2M, net income -$52.1MQuarter to 30 Apr 2025: revenue $17.2M, net income -$52.1MQuarter to 31 Jul 2025: revenue $19.4M, net income -$25.8MQuarter to 31 Jul 2025: revenue $19.4M, net income -$25.8MQuarter to 31 Oct 2025: revenue $22.6M, net income -$32.8MQuarter to 31 Oct 2025: revenue $22.6M, net income -$32.8MQuarter to 31 Jan 2026: revenue $24.6M, net income -$34.2MQuarter to 31 Jan 2026: revenue $24.6M, net income -$34.2MQuarter to 30 Apr 2026: revenue $28.6M, net income -$38.8MQuarter to 30 Apr 2026: revenue $28.6M, net income -$38.8MQuarter to 31 Jul 2026: revenue $31.0M, net income -$44.1MQuarter to 31 Jul 2026: revenue $31.0M, net income -$44.1M
31 Jul 2024RevenueNet incomeNet losstallest bar $52.1M31 Jul 2026
See the numbers
Quarter toRevenueNet income
31 Jul 2026$31.0M-$44.1M
30 Apr 2026$28.6M-$38.8M
31 Jan 2026$24.6M-$34.2M
31 Oct 2025$22.6M-$32.8M
31 Jul 2025$19.4M-$25.8M
30 Apr 2025$17.2M-$52.1M
31 Jan 2025$15.1M-$21.5M
31 Oct 2024$14.7M-$20.4M
31 Jul 2024$12.8M-$19.9M
Fundamentals, 12 months to 31 Jul 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $106.7M $66.4M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +61% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$149.9M -$119.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.67 -$4.51
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 53.9% 43.5% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -134% -176% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -140% -180% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -73.7% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$122.8M -$110.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $244.7M $201.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $72.5M $41.5M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$172.2M (net cash) -$159.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.33 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.73
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 14.0 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 12.4 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.7 2.8

Latest = 12 months to 31 Jul 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Kestra Medical TechnologiesKMTS (this company) $1.5Bloss14.0+61%-140%
PROCEPT BioRoboticsPRCT $1.4Bloss4.0+17%-32.6%
Inspire Medical SystemsINSP $1.6B15.81.8-0.2%11.4%
LeMaitre VascularLMAT $1.7B26.66.3+12%23.5%
NovoCureNVCR $1.3Bloss1.7+13%-16.8%
Tandem Diabetes CareTNDM $1.2Bloss1.1+6.8%-4.6%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$7.6M

bought $0, sold $7.6M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+11%

121 13F filers vs 109

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

99%

58.9M shares held by 13F filers (30 Sep 2026) of 59.6M outstanding (11 Sep 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.9%

4.1M shares sold short (30 Oct 2026) of 59.6M outstanding (11 Sep 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.2

4.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+20%

3.4M shares sold short in the report before, 4.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

72%

72% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 68%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+60%

$31.0M vs $19.4M (quarter ended 31 Jul 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+2.1%

$8.3M vs $8.2M (quarter ended 31 Jul 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

20

20 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

20×

20 articles in the last 7 days; its usual week has 1.

Price $25.10 on 20 Nov 2026, +0.4% over 12 months (12-month range $17.87 to $31.63)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $15.8M in the last 12 months (the 12 months before: $289K).
Revenue per quarter. Revenue $31.0M in the latest quarter, +60% on a year earlier.
Capital spending per quarter. Capital spending $8.3M in the latest quarter, +2.1% on a year earlier.
Institutional holders (13F filers). 121 13F filers reported holding it in the latest 13F quarter, +59% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Jul 2026Sharp changeQuarterly revenue change: quarterly revenue change, 28.6M vs usual 17.2M (2026-04-30); 1.7x the same period a year earlier
14 Jul 20268-K and other filingsA major agreement ended
12 May 2026Sharp changeShort interest spike: short interest spike, 3.5M vs usual 2.1M (2026-04-30); 3.6x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 3.6M vs usual 2.1M (2026-04-15); 4.0x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 3.5M vs usual 2.0M (2026-03-31); 2.9x the same period a year earlier
1 Dec 20258-K and other filingsRegistered new securities for sale (S-1)
6 Jun 20258-K and other filingsDirector or officer change
6 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Mar 20258-K and other filingsDirector or officer change
7 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Mar 20258-K and other filingsRegistered new securities for sale (S-1)
26 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
10 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Sep 2025: $289K published
Month from 1 Jan 2026: -$1.0M published
Month from 1 Feb 2026: -$384K published
Month from 1 Mar 2026: -$104K published
Month from 1 Apr 2026: -$301K published
Month from 1 May 2026: -$314K published
Month from 1 Jun 2026: -$312K published
Month from 1 Jul 2026: -$337K published
Month from 1 Aug 2026: -$5.4M published
Month from 1 Sep 2026: -$511K published
Month from 1 Oct 2026: -$6.6M published
Month from 1 Nov 2026: -$521K published
Revenue per quarter
Quarter ended 31 Jul 2024: $12.8M; public on 13 Sep 2025
Quarter ended 31 Oct 2024: $14.7M; public on 12 Dec 2025
Quarter ended 31 Jan 2025: $15.1M; public on 18 Mar 2026
Quarter ended 30 Apr 2025: $17.2M; public on 18 Jul 2025
Quarter ended 31 Jul 2025: $19.4M, +52% on a year earlier; public on 13 Sep 2025
Quarter ended 31 Oct 2025: $22.6M, +53% on a year earlier; public on 12 Dec 2025
Quarter ended 31 Jan 2026: $24.6M, +63% on a year earlier; public on 18 Mar 2026
Quarter ended 30 Apr 2026: $28.6M, +66% on a year earlier; public on 15 Jul 2026
Quarter ended 31 Jul 2026: $31.0M, +60% on a year earlier; public on 15 Sep 2026
Capital spending per quarter
Quarter ended 31 Jul 2024: $7.0M; public on 13 Sep 2025
Quarter ended 31 Oct 2024: $4.4M; public on 12 Dec 2025
Quarter ended 31 Jan 2025: $4.1M; public on 18 Mar 2026
Quarter ended 30 Apr 2025: $7.4M; public on 18 Jul 2025
Quarter ended 31 Jul 2025: $8.2M, +16% on a year earlier; public on 13 Sep 2025
Quarter ended 31 Oct 2025: $7.3M, +63% on a year earlier; public on 12 Dec 2025
Quarter ended 31 Jan 2026: $9.8M, +141% on a year earlier; public on 18 Mar 2026
Quarter ended 30 Apr 2026: $9.7M, +31% on a year earlier; public on 15 Jul 2026
Quarter ended 31 Jul 2026: $8.3M, +2.1% on a year earlier; public on 15 Sep 2026
Institutional holders (13F filers)
31 Mar 2025 report: 63; public on 15 May 2025
30 Jun 2025 report: 70; public on 14 Aug 2025
30 Sep 2025 report: 76; public on 14 Nov 2025
31 Dec 2025 report: 103; public on 17 Feb 2026
31 Mar 2026 report: 99; public on 15 May 2026
30 Jun 2026 report: 109; public on 14 Aug 2026
30 Sep 2026 report: 121; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is cash from operations, quarter at -$32.3M (31 Jul 2026), 76% below its normal quarter of -$18.4M; higher than 11% of its own history.
  • Quarterly revenue change: reported revenue of $28.6M for the quarter ended 30 Apr 2026, 1.7× the same quarter last year Public on 16 Jul 2026.
  • Insider net buying (open market): Insiders sold a net $15.8M in the last 12 months (the 12 months before: $289K).
  • Capital spending per quarter: Capital spending $8.3M in the latest quarter, +2.1% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 36 insider trades

Last 90 days: 12 sales, $7.6M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Brian Daniel WebsterSee RemarksSellplanned in advance (10b5-1)15,000$28.46$427KForm 4
5 Nov 2026Timothy P. MoranChief Business OfficerSell3,192$29.56$94KForm 4
29 Oct 2026Vaseem MahboobChief Financial OfficerSellplanned in advance (10b5-1); after exercising options79,500$30.30$2.4MForm 4
29 Oct 2026Traci S UmbergerSee RemarksSellplanned in advance (10b5-1); after exercising options30,000$30.03$901KForm 4
22 Oct 2026Traci S UmbergerSee RemarksSellplanned in advance (10b5-1); after exercising options100,000$27.18$2.7MForm 4
22 Oct 2026Brian Daniel WebsterSee RemarksSellplanned in advance (10b5-1)15,000$29.56$443KForm 4
1 Oct 2026Raymond W CohenDirectorSell3,330$29.28$98KForm 4
23 Sep 2026Elizabeth KwoDirectorSell4,010$24.26$97KForm 4

121 institutions reported shares at the end of Q3 2026, 99% of the shares outstanding; 22 opened a position, 9 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Bain Capital Investors LLC25.2M42.3%$712.1MNo change
FMR LLC (Fidelity)6.0M10.0%$168.5M+434K+7.9%
T. Rowe Price Associates Inc5.3M8.97%+374K+7.5%
Andera Partners2.7M4.58%$77.2MNo change
Yu Fan2.3M3.83%$64.6MNo change
BlackRock, Inc.2.2M3.75%$63.1M+366K+20%
Brown Advisory Inc1.8M3.06%$51.6M-85K-4.5%
Alliancebernstein L.P.1.4M2.30%$38.8M-106K-7.2%
Vanguard Capital Management LLC1.3M2.23%$37.6M+154K+13%
Eventide Asset Management, LLC1.3M2.11%$35.6M-188K-13%

Company events

All 10 company events

In 12 months: 2 major agreements, 1 share registration, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Jul 2026Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
4 Dec 2025Signed a major agreement8-K
1 Dec 2025Registered new securities for sale (S-1)S-1
6 Jun 2025Director or officer change8-K
7 Mar 2025Director or officer change; Signed a major agreementSame filing: changed shareholder rights, changed its bylaws or fiscal year8-K
3 Mar 2025Registered new securities for sale (S-1)S-1/A
26 Feb 2025Registered new securities for sale (S-1)S-1/A
10 Feb 2025Registered new securities for sale (S-1)S-1

The 5 newest of 78 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 16 Jul 2026Financials change

    reported revenue of $28.6M for the quarter ended 30 Apr 2026, 1.7× the same quarter last year.

    Same quarter last year: $17.2M; its normal quarter is $17.2M.

    See the evidence
    This period
    $28.6M (the quarter ended 30 Apr 2026)
    Normal quarter (median of 7 earlier)
    $17.2M
    Typical spread (median absolute deviation)
    $2.5M
    How far from its usual level
    +3.0
    Same quarter last year
    $17.2M
    History used
    638 days
    2024-07-31: $12.8M2024-10-31: $14.7M2025-01-31: $15.1M2025-04-30: $17.2M2025-07-31: $19.4M2025-10-31: $22.6M2026-01-31: $24.6M2026-04-30: $28.6M
    the quarter ended 30 Apr 20267 earlier quartersnormal: $17.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 14 Jul 2026Filings record

    A major agreement ended

  3. 12 May 2026Short interest and volume change

    had 3.5M shares sold short in the 30 Apr 2026 report, 3.6× the same report last year.

    Same report last year: 950K; its normal report is 2.1M.

    See the evidence
    This period
    3.5M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    232K
    How far from its usual level
    +4.0
    Same report last year
    950K
    History used
    412 days
    2025-04-30: 950K2025-05-15: 951K2025-05-30: 951K2025-06-13: 1.1M2025-06-30: 2.2M2025-07-15: 2.3M2025-07-31: 2.1M2025-08-15: 2.1M2025-08-29: 2.2M2025-09-15: 2.1M2025-09-30: 2.0M2025-10-15: 2.0M2025-10-31: 1.6M2025-11-14: 1.8M2025-11-28: 1.9M2025-12-15: 2.0M2025-12-31: 2.4M2026-01-15: 2.3M2026-01-30: 2.3M2026-02-13: 2.4M2026-02-27: 2.7M2026-03-13: 2.8M2026-03-31: 3.5M2026-04-15: 3.6M2026-04-30: 3.5M
    the 30 Apr 2026 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 25 Apr 2026Short interest and volume change

    had 3.6M shares sold short in the 15 Apr 2026 report, 4.0× the same report last year.

    Same report last year: 914K; its normal report is 2.1M.

    See the evidence
    This period
    3.6M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    233K
    How far from its usual level
    +4.5
    Same report last year
    914K
    History used
    397 days
    2025-04-15: 914K2025-04-30: 950K2025-05-15: 951K2025-05-30: 951K2025-06-13: 1.1M2025-06-30: 2.2M2025-07-15: 2.3M2025-07-31: 2.1M2025-08-15: 2.1M2025-08-29: 2.2M2025-09-15: 2.1M2025-09-30: 2.0M2025-10-15: 2.0M2025-10-31: 1.6M2025-11-14: 1.8M2025-11-28: 1.9M2025-12-15: 2.0M2025-12-31: 2.4M2026-01-15: 2.3M2026-01-30: 2.3M2026-02-13: 2.4M2026-02-27: 2.7M2026-03-13: 2.8M2026-03-31: 3.5M2026-04-15: 3.6M
    the 15 Apr 2026 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 11 Apr 2026Short interest and volume change

    had 3.5M shares sold short in the 31 Mar 2026 report, 2.9× the same report last year.

    Same report last year: 1.2M; its normal report is 2.0M.

    See the evidence
    This period
    3.5M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    277K
    How far from its usual level
    +3.6
    Same report last year
    1.2M
    History used
    382 days
    2025-03-31: 1.2M2025-04-15: 914K2025-04-30: 950K2025-05-15: 951K2025-05-30: 951K2025-06-13: 1.1M2025-06-30: 2.2M2025-07-15: 2.3M2025-07-31: 2.1M2025-08-15: 2.1M2025-08-29: 2.2M2025-09-15: 2.1M2025-09-30: 2.0M2025-10-15: 2.0M2025-10-31: 1.6M2025-11-14: 1.8M2025-11-28: 1.9M2025-12-15: 2.0M2025-12-31: 2.4M2026-01-15: 2.3M2026-01-30: 2.3M2026-02-13: 2.4M2026-02-27: 2.7M2026-03-13: 2.8M2026-03-31: 3.5M
    the 31 Mar 2026 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 31 Mar 2026Insiders record

    COHEN RAYMOND W (director) bought 10,000 shares of KMTS ($199,800) (dated 30 Mar 2026)

  7. 1 Dec 2025Filings record

    Registered new securities for sale (S-1)

  8. 16 Sep 2025Insiders record

    Ford Alfred J Jr (Chief Commercial Officer) bought 20,000 shares of KMTS ($340,000) [amended] (dated 15 Sep 2025)

  9. 16 Sep 2025Insiders record

    Umberger Traci S (See Remarks) bought 13,500 shares of KMTS ($229,500) [amended] (dated 15 Sep 2025)

  10. 9 Sep 2025Insiders record

    COHEN RAYMOND W (director) bought 17,000 shares of KMTS ($289,000) (dated 8 Sep 2025)

  11. 6 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 6 Jun 2025Filings record

    Director or officer change

  13. 7 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 7 Mar 2025Filings record

    Director or officer change

  15. 3 Mar 2025Filings record

    Registered new securities for sale (S-1)

  16. 26 Feb 2025Filings record

    Registered new securities for sale (S-1)

  17. 10 Feb 2025Filings record

    Registered new securities for sale (S-1)

Not listed: 50 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001877184
Ticker
KMTS
Domain
kestramedical.com
Hq location
WA|KIRKLAND|98033 (1 unverified)
Name
Kestra Medical Technologies, Ltd.
  • SEC Form 13F institutional holdings63 data points31 Mar 2025 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)25 records10 Feb 2025 to 14 Sep 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)162 data points30 Apr 2023 to 11 Sep 2026
  • SEC Form 4 insider transactions36 records, 84 data points8 Sep 2025 to 19 Nov 2026
  • FINRA short interest (twice monthly)119 data points14 Mar 2025 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)864 data points6 Mar 2025 to 20 Nov 2026